Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $14.00 Price Target at Piper Sandler

Perspective Therapeutics (NYSEAMERICAN:CATX) had its target price lowered by stock analysts at Piper Sandler from $16.00 to $14.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s target price points to a potential upside of 366.67% from the stock’s current price.

CATX has been the subject of several other reports. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a report on Friday, July 24th. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $12.38.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN CATX opened at $3.00 on Tuesday. Perspective Therapeutics has a twelve month low of $1.96 and a twelve month high of $6.16. The stock’s 50 day moving average price is $3.10 and its 200-day moving average price is $3.93.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its earnings results on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.03. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. As a group, research analysts anticipate that Perspective Therapeutics will post -1.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Avidity Partners Management LP increased its stake in Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after acquiring an additional 2,839,266 shares during the last quarter. Yu Fan bought a new position in Perspective Therapeutics during the first quarter valued at $4,401,000. Seven Fleet Capital Management LP purchased a new position in Perspective Therapeutics during the 1st quarter valued at $1,581,000. Commodore Capital LP bought a new position in Perspective Therapeutics in the 1st quarter worth about $26,424,000. Finally, Ally Bridge Group NY LLC purchased a new position in shares of Perspective Therapeutics during the first quarter worth approximately $3,864,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.